CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Icelandic pharmaceutical maker Alvotech (ALVO) readies SPAC

By Robert Davis

21:14, 7 December 2021

Laboratory test tubes and solution with stethoscope background
Alvotech makes biosimilar medicines - Photo: Shutterstock

Icelandic pharmaceutical company Alvotech announced on Tuesday that it is going public thanks to a merger with special purpose acquisition company (SPAC) Oaktree Acquisition.

Oaktree’s stock was flat during Tuesday’s trading session, losing just 0.1% of its value to $9.86 per share.

Alvotech will trade on the Nasdaq under the ticker “ALVO” once it is listed.

Merger details

According to a press release, the deal gives Alvotech an assumed valuation of $2.5bn (£1.88bn).  

The company is seeking to raise approximately $450m from its offering. The proceeds will go toward further development of its platform and portfolio of biosimilar medicines.

Investors in the deal include Suvretta Capital, CVC Capital Partners, and Icelandic institutions like Arctica Finance, Arion Bank and Landsbankinn.

Alvotech expects to list its shares at $10 apiece when it goes public.

Robert Wessman, chair and founder of Alvotech, described the deal as “an important milestone” because the company is “perfectly positioned to rapidly scale our portfolio with a like-minded partner who understands the intricacies of our business and our industry.”

About Alvotech

Founded in 2013, Alvotech focusses exclusively on developing affordable biosimilar medicines for the global market.


44,288.45 Price
+1.970% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030


16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0


2,004.85 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.50

According to the Australian Department of Health, biosimilar medicines are produced with proteins that are naturally occurring in the human body and mimic biological medicines. These medicines are often used to treat cancer, rheumatoid arthritis and diabetes, among other diseases.

Alvotech is working to lower the cost of these medicines by becoming a global supplier of the medicines.

So far, the company has received more than $1bn in investments, according to the press release.

Growing market

Alvotech is also operating in a market that is set to see explosive growth in the next few years.

A market analysis by research firm BioSpace shows the biologic and biosimilar medicine industry is expected to increase to a valuation of $68bn by 2028 at a compound annual growth rate of 24.6%.

Alvotech said it is “uniquely positioned” to capitalise on this growth because of its investments in the business’ critical distribution infrastructure.

The company has already forged partnerships with commercial partners in more than 60 countries.

Read more: Archaea Energy receives post SPAC bump

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading